A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) (NCT06312176)
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to compare sacituzumab tirumotecan as a single agent, and in combination with pembrolizumab, versus Treatment of Physician's Choice (TPC) in participants with hormone receptor positive/human epidermal growth factor receptor-2 negative (HR+/HER2-) unresectable locally advanced, or metastatic, breast cancer. The primary hypotheses are that sacituzumab tirumotecan as a single agent and sacituzumab tirumotecan plus pembrolizumab are superior to TPC with respect to progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR) in all participants.
Who can join: Review the eligibility criteria below.
Location: Ironwood Cancer & Research Centers ( Site 0066) — Chandler, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (259 Sites)
Showing the first 25 of 259 sites.
- Ironwood Cancer & Research Centers ( Site 0066) — Chandler, Arizona
- Banner MD Anderson Cancer Center-Oncology ( Site 0004) — Gilbert, Arizona
- Providence Medical Foundation-Oncology ( Site 0020) — Fullerton, California
- Moores Cancer Center ( Site 0059) — La Jolla, California
- Cancer and Blood Specialty Clinic ( Site 0001) — Los Alamitos, California
- University of Colorado Anschutz Medical Campus ( Site 0061) — Aurora, Colorado
- UCHealth Cherry Creek Medical Center ( Site 0094) — Denver, Colorado
- University of Colorado Health - Highlands Ranch Hospital ( Site 0095) — Highlands Ranch, Colorado
- Yale Cancer Center ( Site 0060) — New Haven, Connecticut
- Stamford Hospital ( Site 0049) — Stamford, Connecticut
- AdventHealth Altamonte Springs ( Site 0021) — Altamonte Springs, Florida
- University of Florida College of Medicine ( Site 0063) — Gainesville, Florida
- Orlando Health Cancer Institute ( Site 0011) — Orlando, Florida
- Archbold Memorial Hospital-Lewis Hall Singletary Oncology Center ( Site 0032) — Thomasville, Georgia
- Rush University Medical Center ( Site 0079) — Chicago, Illinois
- University of Chicago Medical Center ( Site 0067) — Chicago, Illinois
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0053) — Edgewood, Kentucky
- Mary Bird Perkins Cancer Center-Breast & GYN Pavilion ( Site 0042) — Baton Rouge, Louisiana
- Greenebaum Comprehensive Cancer Center ( Site 0036) — Baltimore, Maryland
- Mercy Medical Center - Baltimore-Medical Oncology and Hematology ( Site 0028) — Baltimore, Maryland
- Holy Cross Hospital ( Site 0073) — Silver Spring, Maryland
- Dana-Farber Cancer Institute-Breast Oncology Center ( Site 0037) — Boston, Massachusetts
- Henry Ford Health ( Site 0002) — Detroit, Michigan
- Saint Luke's Cancer Institute ( Site 0027) — Kansas City, Missouri
- Washington University School of Medicine ( Site 0076) — St Louis, Missouri
📞 Contact the Study Coordinator
Phone: (888) 577-8839
Email: Trialsites@msd.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Breast Neoplasms
- Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
- (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
- Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
- Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
- Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer — Springdale, Arkansas
- The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California
Explore by condition: All Breast Neoplasms clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.